Regen BioPharma, Inc. Makes Three Presentations at the 13th International Symposium on Myelodysplastic Syndromes Held April 29 to May 2, 2015 in Washington, DC
Regen Well Received at Conference, Resulting in Numerous Collaborative Opportunities
SAN DIEGO, CA--(Marketwired - May 5, 2015) - Regen BioPharma Inc. (OTCBB: RGBP) (OTC PINK: RGBP) announced today that the Company has made presentations at 13th International Symposium on Myelodysplastic Syndromes held April 29 to May 2, 2015 in Washington, D.C.
Dr. Christine Ichim, Regen's Director of Molecular Therapeutics, made two oral presentations and one poster presentation at the conference:
1. "Technique for establishment of long term in vitro cultures of primary MDS cells" and
2. "NR2F6 (EAR-2) is a novel leukemia and MDS oncogene, over-expressed in patients, that inhibits hematopoietic differentiation and blocks erythropoietic differentiation at the proerythrocyte stage"
3. "HemaXellerate I™, Autologous adipose stromal vascular fraction cells, for severe aplastic anemia"
The subject of the first presentation was methods for growing myelodysplastic syndrome (MDS) cells in culture. "This is important as no one currently has been able to establish MDS cell lines. In this way, MDS is such a hard disease to treat since in vitro cells cannot be cultured for laboratory experiments. It is therefore impossible to conduct drug discovery and conduct research that unlocks the underlying biological mechanisms of this disease," according to Dr. Ichim, "Regen presented the first methodology for growing MDS cells in vitro, which positions the Company to be a leader in this field."
The subject of the second presentation was the discovery of gene NR2F6 as a drug target for differentiation therapy in treating leukemic and MDS patients suffering from anemia. This presentation showed that NR2F6 is a gene that both prevents the formation of red blood cells by blocking their differentiation and keeps them in a stem cell state.
The third presentation covered HemaXellerate as an autologous therapy for treating aplastic anemia. Regen presented the rational for the therapy and discussed HemaXellerate Investigational New Drug (IND) application which has been submitted to the USFDA.
A Company Spokesperson noted that, as a result of these presentations, Regen has been approached by numerous entities working in the area of MDS and Leukemia that are interested in possible future collaborations, co-development and other potential involvements with the Company.
ABOUT REGEN BIOPHARMA INC.: Regen BioPharma Inc. is a publicly traded biotechnology company (OTCBB: RGBP) and (OTC PINK: RGBP). The Company is focused on identifying undervalued regenerative medicine applications in the stem cell space and rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. Currently the Company is focused on gene silencing therapy for treating cancer, telomeres and small molecule therapies, along with developing stem cell treatments for aplastic anemia. Regen is majority controlled by Bio-Matrix Scientific Group Inc. (OTC PINK: BMSN).
Disclaimer: This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
CONTACT INFORMATION
Contact:
Regen BioPharma Inc.
David R. Koos, PhD
Chairman & Chief Executive Officer
619-702-1404
www.regenbiopharma.com
Hit the ask early and often!
TRAZ
